| Jul 31 |
CareDx: Q2 Earnings Snapshot
|
| Jul 31 |
CareDx Reports Second Quarter 2024 Results and Increases Revenue Guidance
|
| Jul 31 |
Investing in CareDx (NASDAQ:CDNA) a year ago would have delivered you a 79% gain
|
| Jul 30 |
CareDx Q2 2024 Earnings Preview
|
| Jul 16 |
CareDx to Report Second Quarter 2024 Financial Results
|
| Jul 15 |
CareDx: Benefiting From Some Certainty
|
| Jun 3 |
Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients
|
| May 30 |
AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress
|
| May 29 |
CareDx Reiterates Position that it Does Not Infringe the ‘544 Patent, Injunction Motion is Irrelevant
|
| May 29 |
CareDx to Participate in Upcoming Investor Conferences
|
